Puma Biotechnology Inc (PBYI) USD0.0001

Sell:$3.03Buy:$3.04$0.06 (2.01%)

NASDAQ:0.55%
Market closed | Prices delayed by at least 15 minutes
Sell:$3.03
Buy:$3.04
Change:$0.06 (2.01%)
Market closed | Prices delayed by at least 15 minutes
Sell:$3.03
Buy:$3.04
Change:$0.06 (2.01%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.

Key people

Alan H. Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Maximo F. Nougues
Chief Financial Officer
Alvin Wong
Chief Scientific Officer
Douglas Hunt
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
Jeff J. Ludwig
Chief Commercial Officer
Jay M. Moyes
Lead Independent Director
Alessandra Cesano
Independent Director
Allison Dorval
Independent Director
Michael P. Miller
Independent Director
Adrian M. Senderowicz
Independent Director
Click to see more

Key facts

  • EPIC
    PBYI
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US74587V1070
  • Market cap
    $147.84m
  • Employees
    172
  • Shares in issue
    49.63m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.